UNSPSC 51432113: Guanoclor sulfate

This classification denotes an antihypertensive agent with the molecular formula 2C9H12Cl2N4O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q1U97XK18R, chemically known as 2-(2,6-dichlorophenoxy)ethylaminoguanidine sulfate but more generally known as guanoclor sulfate, which bears US NIH Compound Identifier 71835. European Medicines Agency schedules Guanoclor sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14036MIG.

Most nations, for tariff and trade purposes, schedule guanoclor sulfate under HS 29280090 and SITC 51486. As of Q4 2014, GUANOCLOR SULFATE remains US FDA's Preferred Term for this commodity. Guanoclor sulfate bears US NLM identifiers UMLS ID C1881016 and NCI Concept Code C65834. SMILES: C1CC(C(C(C1)CL)OCCNNC(=N)N)CL.C1CC(C(C(C1)CL)OCCNNC(=N)N)CL.OS(=O)(=O)O.

UNSPSC 51432113 Guanoclor sulfate is a Commodity code that in practice encompasses emergency and clinical medications procured by state and local health agencies, fire departments, and pharmacy benefit programs — not guanoclor sulfate specifically, but rather the broader class of advanced life support drugs, generic pharmaceuticals, and OTC products that public bodies buy through sealed bidding, cooperative purchasing agreements, and market-intelligence RFIs. State and local issuing bodies soliciting under this code range from municipal fire departments and city purchasing offices to state health commissions and multistate cooperative purchasing alliances; Tampa Fire Rescue and the Texas Health and Human Services Commission appear in recent activity, as does the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which pools buying power across state and local members including Oregon. Recent solicitations show demand for specific emergency medications (labetalol, epinephrine, adenosine, diltiazem), generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription fulfillment capabilities.

Activity in this code concentrates in Florida, Texas, and Minnesota as of early 2026, with multistate cooperative purchasing adding geographic breadth. The City of Tampa's Purchasing Department posted IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications with an April 8, 2026 response deadline and an estimated contract value of $40,000 — a one-year term with two optional one-year renewals and a Small Local Business Enterprise sheltered-market 5 percent bid discount not to exceed $10,000. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities with a March 26, 2026 deadline, requiring NDC-level specificity, cGMP and DSCSA certification, and relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — a market-intelligence phase preceding formal RFP issuance, with no award value or timeline specified.